Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy aTyr Pharma stock | $4.05

Own aTyr Pharma stock in just a few minutes.

Fact checked

aTyr Pharma, Inc is a biotechnology business based in the US. aTyr Pharma shares (LIFE) are listed on the NASDAQ and all prices are listed in US Dollars. aTyr Pharma employs 39 staff and has a trailing 12-month revenue of around USD$8.5 million.

How to buy shares in aTyr Pharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for aTyr Pharma. Find the stock by name or ticker symbol: LIFE. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until aTyr Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$4.05, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of aTyr Pharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of aTyr Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

aTyr Pharma share price

Use our graph to track the performance of LIFE stocks over time.

aTyr Pharma shares at a glance

Information last updated 2020-12-02.
Latest market closeUSD$4.05
52-week rangeUSD$2.13 - USD$6.95
50-day moving average USD$3.3763
200-day moving average USD$3.8384
Wall St. target priceUSD$13.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-10.206

Buy aTyr Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy aTyr Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

aTyr Pharma price performance over time

Historical closes compared with the close of $4.05 from 2020-12-09

1 week (2021-01-09) N/A
1 month (2020-12-18) -0.25%
3 months (2020-10-16) 18.08%
6 months (2020-07-17) -20.43%
1 year (2020-01-17) -34.25%
2 years (2019-01-18) 606.68%
3 years (2018-01-18) 4.1
5 years (2016-01-16) N/A

aTyr Pharma financials

Revenue TTM USD$8.5 million
Gross profit TTM USD$-13,626,000
Return on assets TTM -24.79%
Return on equity TTM -59.35%
Profit margin -202.02%
Book value $3.219
Market capitalisation USD$42.8 million

TTM: trailing 12 months

Shorting aTyr Pharma shares

There are currently 68,994 aTyr Pharma shares held short by investors – that's known as aTyr Pharma's "short interest". This figure is 9.2% up from 63,171 last month.

There are a few different ways that this level of interest in shorting aTyr Pharma shares can be evaluated.

aTyr Pharma's "short interest ratio" (SIR)

aTyr Pharma's "short interest ratio" (SIR) is the quantity of aTyr Pharma shares currently shorted divided by the average quantity of aTyr Pharma shares traded daily (recently around 53483.720930233). aTyr Pharma's SIR currently stands at 1.29. In other words for every 100,000 aTyr Pharma shares traded daily on the market, roughly 1290 shares are currently held short.

However aTyr Pharma's short interest can also be evaluated against the total number of aTyr Pharma shares, or, against the total number of tradable aTyr Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case aTyr Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 aTyr Pharma shares in existence, roughly 10 shares are currently held short) or 0.0073% of the tradable shares (for every 100,000 tradable aTyr Pharma shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against aTyr Pharma.

Find out more about how you can short aTyr Pharma stock.

aTyr Pharma share dividends

We're not expecting aTyr Pharma to pay a dividend over the next 12 months.

Have aTyr Pharma's shares ever split?

aTyr Pharma's shares were split on a 1:14 basis on 1 July 2019. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your aTyr Pharma shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for aTyr Pharma shares which in turn could have impacted aTyr Pharma's share price.

aTyr Pharma share price volatility

Over the last 12 months, aTyr Pharma's shares have ranged in value from as little as $2.13 up to $6.95. A popular way to gauge a stock's volatility is its "beta".

LIFE.US volatility(beta: 1.97)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while aTyr Pharma's is 1.9673. This would suggest that aTyr Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

aTyr Pharma overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children's Hospital. It also has license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan; and a research collaboration with the Medical University of South Carolina to develop therapeutic antibodies that selectively target specific NRP2 isoforms. The company was founded in 2005 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site